Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.70 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 5/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20597647 | 0.98 | CYP4F2 (0.73) | CYP4F2CYP4A11NPSR1CETPP2RX7 | |
| SCHEMBL6627249 | 0.96 | CYP4F2 (0.65) | CYP4F2CYP4A11NPSR1CETPTSHR | |
| SCHEMBL6628282 | 0.95 | CYP4F2 (0.67) | CYP4F2CYP4A11NPSR1CETPP2RX7 | |
| SCHEMBL6627868 | 0.87 | CYP4F2 (0.61) | CYP4F2CYP4A11NPSR1P2RX7MAPT | |
| SCHEMBL28840765 | 0.85 | CYP4F2 (0.59) | CYP4F2CYP4A11NPSR1CETPP2RX7 | |
| SCHEMBL3150942 | 0.84 | CYP4F2 (0.72) | CYP4F2CYP4A11NPSR1CETPMEN1 | |
| SCHEMBL22070954 | 0.84 | CYP4F2 (0.96) | CYP4F2CYP4A11NPSR1CETPP2RX7 | |
| SCHEMBL23309175 | 0.82 | CYP4F2 (0.93) | CYP4F2CYP4A11NPSR1CETPP2RX7 | |
| SCHEMBL22098215 | 0.82 | CYP4F2 (1.00) | CYP4F2CYP4A11NPSR1CETPP2RX7 | |
| SCHEMBL22098378 | 0.82 | CYP4F2 (1.00) | CYP4F2CYP4A11NPSR1CETPP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2806898-B1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING VLA-4 | HOFFMANN LA ROCHE (CH) | 2018-07-18 | — | — | EP | disclosed |
| EP-2806898-B1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING VLA-4 | HOFFMANN LA ROCHE (CH) | 2018-07-18 | — | — | EP | disclosed |
| US-9447035-B2 | Integrin antagonist conjugates for targeted delivery to cells expressing VLA-4 | HOFFMANN-LA ROCHE INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-9447035-B2 | Integrin antagonist conjugates for targeted delivery to cells expressing VLA-4 | HOFFMANN-LA ROCHE INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-9447035-B2 | Integrin antagonist conjugates for targeted delivery to cells expressing VLA-4 | HOFFMANN-LA ROCHE INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20150031715-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING VLA-4 | HOFFMANN-LA ROCHE INC. | 2015-01-29 | — | — | US | disclosed |
| US-20150031715-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING VLA-4 | HOFFMANN-LA ROCHE INC. | 2015-01-29 | — | — | US | disclosed |
| US-20150031715-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING VLA-4 | HOFFMANN-LA ROCHE INC. | 2015-01-29 | — | — | US | disclosed |
| EP-2806898-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING VLA-4 | F.HOFFMANN-LA ROCHE AG (CH) | 2014-12-03 | — | — | EP | disclosed |
| CN-104023751-A | Integrin Antagonist Conjugates For Targeted Delivery To Cells Expressing Vla-4 | HOFFMANN LA ROCHE | 2014-09-03 | — | — | CN | disclosed |
| CN-1342140-A | Thioamide derivatives | HOFFMANN LA ROCHE (CH) | 2002-03-27 | — | — | CN | disclosed |
| US-20020028933-A1 | Thioamide derivatives | HULL KENNETH GREGORY (US) | 2002-03-07 | — | — | US | disclosed |
| US-20020010338-A1 | PHENYL-KETO-IMIDAZOLIDINE THIOAMIDE DERIVATIVES | HULL KENNETH G (US) | 2002-01-24 | — | — | US | disclosed |
| EP-1154993-A1 | THIOAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-21 | — | — | EP | disclosed |
| US-20010041799-A1 | Diephenyl carbocyclic thioamide derivatives | HULL KENNETH G (US) | 2001-11-15 | — | — | US | disclosed |
| US-6288267-B1 | AROMATIC CARBOXY THIOAMIDES WITH AMIDES AS DRUGS TO COUNTERACT INFLAMMATION | HOFFMANN-LA ROCHE INC. | 2001-09-11 | — | — | US | disclosed |
| CN-1276785-A | N-aroylphenylalanine derivs. | HOFFMANNN LA ROCHE AG F (CH) | 2000-12-13 | — | — | CN | disclosed |
| WO-2000048994-A1 | THIOAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-08-24 | — | — | WO | disclosed |
| EP-1005446-A1 | N-AROYLPHENYLALANINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-07 | — | — | EP | disclosed |
| WO-1999010313-A1 | N-AROYLPHENYLALANINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031715-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING VLA-4 | ITGAV, ITGA1, ITGA4 | CYP4F2 4345/4885CYP4A11 4674/4885NPSR1 158/4885 |
| US-20020028933-A1 | Thioamide derivatives | VCAM1, ICAM1, LTB4R | CYP4F2 589/4885CYP4A11 399/4885NPSR1 2437/4885 |
| US-20020010338-A1 | PHENYL-KETO-IMIDAZOLIDINE THIOAMIDE DERIVATIVES | VCAM1, ICAM1, KCNA4 | CYP4F2 1188/4885CYP4A11 464/4885NPSR1 3217/4885 |
| US-20010041799-A1 | Diephenyl carbocyclic thioamide derivatives | VCAM1, ICAM1, LTB4R | CYP4F2 693/4885CYP4A11 291/4885NPSR1 2695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.